Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: semaglutide

First Posted Date: 2017-01-13

Last Posted Date: 2020-03-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 731

Registration Number: NCT03021187

Locations: 🇷🇺
Novo Nordisk Investigational Site, St. Petersburg, Russian Federation

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: Liraglutide
Drug: Placebo
Drug: Semaglutide

First Posted Date: 2017-01-11

Last Posted Date: 2021-01-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 243

Registration Number: NCT03018028

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Phase 1

Completed

Conditions: Obesity
Metabolism and Nutrition Disorder

Interventions: Drug: NNC0194-0499
Drug: Placebo

First Posted Date: 2017-01-09

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 56

Registration Number: NCT03015207

Locations: 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Dulaglutide
Drug: Semaglutide

First Posted Date: 2017-01-09

Last Posted Date: 2021-03-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 458

Registration Number: NCT03015220

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yamato-shi, Kanagawa, Japan

A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: Furosemide
Drug: Rosuvastatin
Drug: SNAC
Drug: Semaglutide

First Posted Date: 2017-01-05

Last Posted Date: 2017-12-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 41

Registration Number: NCT03010475

Locations: 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa pegol

First Posted Date: 2016-12-15

Last Posted Date: 2020-02-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 50

Registration Number: NCT02994407

Locations: 🇷🇸
Novo Nordisk Investigational Site, Novi Sad, Serbia

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Phase 2

Completed

Conditions: Hepatobiliary Disorders
Non-alcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: Semaglutide

First Posted Date: 2016-11-22

Last Posted Date: 2021-11-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 320

Registration Number: NCT02970942

Locations: 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom

In-market Utilisation of Liraglutide Used for Weight Management in Europe

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: liraglutide

First Posted Date: 2016-11-18

Last Posted Date: 2023-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 316

Registration Number: NCT02967757

Locations: 🇮🇹
Novo Nordisk Investigational Site, Siena, Italy

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2016-11-16

Last Posted Date: 2020-11-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 303

Registration Number: NCT02964247

Locations: 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Phase 3

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: Placebo
Drug: Liraglutide 3.0 mg

First Posted Date: 2016-11-15

Last Posted Date: 2020-03-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 396

Registration Number: NCT02963922

Locations: 🇹🇷
Novo Nordisk Investigational Site, Izmir, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy